Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heimo Lagler

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Vaccine|September 20, 2012
Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situationHeimo Lagler, Selma Tobudic, Michael Ramharter, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 26, 2024
Prevalence and clinical implications of bloodstream infections in intensive care patients with or without burn injury: a retrospective cohort studyFelix Bergmann, Anselm Jorda, Julia Sollner, et al.
Journal of Global Health|March 3, 2018
Behavioural and clinical predictors for LoiasisJohannes Mischlinger, Luzia Veletzky, Gildas B Tazemda-Kuitsouc, et al.
Vaccine|August 2, 2011
Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccinationHeimo Lagler, Judith M Wenisch, Selma Tobudic, et al.
Plos One|April 13, 2021
Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver diseaseMichael Eder, Haris Omic, Jana Gorges, et al.
Journal of Clinical Microbiology|December 23, 2011
Gemella morbillorum bacteremia after anti-tumor necrosis factor alpha as acne inversa therapyMatthias G Vossen, Klaus B Gattringer, Neda Khalifeh, et al.
Plos One|May 26, 2012
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individualsHeimo Lagler, Katharina Grabmeier-Pfistershammer, Veronique Touzeau-Römer, et al.
Emerging Microbes & Infections|December 6, 2018
Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditisManuel Kussmann, Matthias Karer, Markus Obermueller, et al.
Case Reports in Infectious Diseases|July 11, 2012
The First Case(s) of Botulism in Vienna in 21 Years: A Case ReportMatthias Gerhard Vossen, Klaus-Bernhard Gattringer, Judith Wenisch, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|June 9, 2020
[An Update on the Epidemiological Situation of Alveolar Echinococcosis: Recording and Reporting Structures in Austria, Switzerland and Germany]Julian Schmidberger, Sven Baumann, Wolfgang Kratzer, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Vaccine|September 20, 2012
Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situationHeimo Lagler, Selma Tobudic, Michael Ramharter, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 26, 2024
Prevalence and clinical implications of bloodstream infections in intensive care patients with or without burn injury: a retrospective cohort studyFelix Bergmann, Anselm Jorda, Julia Sollner, et al.
Journal of Global Health|March 3, 2018
Behavioural and clinical predictors for LoiasisJohannes Mischlinger, Luzia Veletzky, Gildas B Tazemda-Kuitsouc, et al.
Vaccine|August 2, 2011
Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccinationHeimo Lagler, Judith M Wenisch, Selma Tobudic, et al.
Plos One|April 13, 2021
Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver diseaseMichael Eder, Haris Omic, Jana Gorges, et al.
Journal of Clinical Microbiology|December 23, 2011
Gemella morbillorum bacteremia after anti-tumor necrosis factor alpha as acne inversa therapyMatthias G Vossen, Klaus B Gattringer, Neda Khalifeh, et al.
Plos One|May 26, 2012
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individualsHeimo Lagler, Katharina Grabmeier-Pfistershammer, Veronique Touzeau-Römer, et al.
Emerging Microbes & Infections|December 6, 2018
Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditisManuel Kussmann, Matthias Karer, Markus Obermueller, et al.
Case Reports in Infectious Diseases|July 11, 2012
The First Case(s) of Botulism in Vienna in 21 Years: A Case ReportMatthias Gerhard Vossen, Klaus-Bernhard Gattringer, Judith Wenisch, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|June 9, 2020
[An Update on the Epidemiological Situation of Alveolar Echinococcosis: Recording and Reporting Structures in Austria, Switzerland and Germany]Julian Schmidberger, Sven Baumann, Wolfgang Kratzer, et al.
Pageof 8